474 related articles for article (PubMed ID: 27552585)
21. Beyond the hype and hope: Critical considerations for intranasal oxytocin research in autism spectrum disorder.
Alvares GA; Quintana DS; Whitehouse AJ
Autism Res; 2017 Jan; 10(1):25-41. PubMed ID: 27651096
[TBL] [Abstract][Full Text] [Related]
22. Oxytocin induces long-lasting adaptations within amygdala circuitry in autism: a treatment-mechanism study with randomized placebo-controlled design.
Alaerts K; Bernaerts S; Prinsen J; Dillen C; Steyaert J; Wenderoth N
Neuropsychopharmacology; 2020 Jun; 45(7):1141-1149. PubMed ID: 32161366
[TBL] [Abstract][Full Text] [Related]
23. Long-term administration of intranasal oxytocin is a safe and promising therapy for early adolescent boys with autism spectrum disorders.
Tachibana M; Kagitani-Shimono K; Mohri I; Yamamoto T; Sanefuji W; Nakamura A; Oishi M; Kimura T; Onaka T; Ozono K; Taniike M
J Child Adolesc Psychopharmacol; 2013 Mar; 23(2):123-7. PubMed ID: 23480321
[TBL] [Abstract][Full Text] [Related]
24. Additive effects of oxytocin receptor gene polymorphisms on reward circuitry in youth with autism.
Hernandez LM; Krasileva K; Green SA; Sherman LE; Ponting C; McCarron R; Lowe JK; Geschwind DH; Bookheimer SY; Dapretto M
Mol Psychiatry; 2017 Aug; 22(8):1134-1139. PubMed ID: 27843152
[TBL] [Abstract][Full Text] [Related]
25. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders.
Guastella AJ; Einfeld SL; Gray KM; Rinehart NJ; Tonge BJ; Lambert TJ; Hickie IB
Biol Psychiatry; 2010 Apr; 67(7):692-4. PubMed ID: 19897177
[TBL] [Abstract][Full Text] [Related]
26. Changes in endogenous oxytocin levels after intranasal oxytocin treatment in adult men with autism: An exploratory study with long-term follow-up.
Alaerts K; Steyaert J; Vanaudenaerde B; Wenderoth N; Bernaerts S
Eur Neuropsychopharmacol; 2021 Feb; 43():147-152. PubMed ID: 33309460
[TBL] [Abstract][Full Text] [Related]
27. Neural modulation of social reinforcement learning by intranasal oxytocin in male adults with high-functioning autism spectrum disorder: a randomized trial.
Kruppa JA; Gossen A; Oberwelland Weiß E; Kohls G; Großheinrich N; Cholemkery H; Freitag CM; Karges W; Wölfle E; Sinzig J; Fink GR; Herpertz-Dahlmann B; Konrad K; Schulte-Rüther M
Neuropsychopharmacology; 2019 Mar; 44(4):749-756. PubMed ID: 30390065
[TBL] [Abstract][Full Text] [Related]
28. Evidence for the involvement of genetic variation in the oxytocin receptor gene (OXTR) in the etiology of autistic disorders on high-functioning level.
Wermter AK; Kamp-Becker I; Hesse P; Schulte-Körne G; Strauch K; Remschmidt H
Am J Med Genet B Neuropsychiatr Genet; 2010 Mar; 153B(2):629-639. PubMed ID: 19777562
[TBL] [Abstract][Full Text] [Related]
29. Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism.
Parker KJ; Oztan O; Libove RA; Sumiyoshi RD; Jackson LP; Karhson DS; Summers JE; Hinman KE; Motonaga KS; Phillips JM; Carson DS; Garner JP; Hardan AY
Proc Natl Acad Sci U S A; 2017 Jul; 114(30):8119-8124. PubMed ID: 28696286
[TBL] [Abstract][Full Text] [Related]
30. A common oxytocin receptor gene (OXTR) polymorphism modulates intranasal oxytocin effects on the neural response to social cooperation in humans.
Feng C; Lori A; Waldman ID; Binder EB; Haroon E; Rilling JK
Genes Brain Behav; 2015 Sep; 14(7):516-25. PubMed ID: 26178189
[TBL] [Abstract][Full Text] [Related]
31. Oxytocin-induced increases in cytokines and clinical effect on the core social features of autism: Analyses of RCT datasets.
Wakuda T; Benner S; Uemura Y; Nishimura T; Kojima M; Kuroda M; Matsumoto K; Kanai C; Inada N; Harada T; Kameno Y; Munesue T; Inoue J; Umemura K; Yamauchi A; Ogawa N; Kushima I; Suyama S; Saito T; Hamada J; Kano Y; Honda N; Kikuchi S; Seto M; Tomita H; Miyoshi N; Matsumoto M; Kawaguchi Y; Kanai K; Ikeda M; Nakamura I; Isomura S; Hirano Y; Onitsuka T; Ozaki N; Kosaka H; Okada T; Kuwabara H; Yamasue H
Brain Behav Immun; 2024 May; 118():398-407. PubMed ID: 38461957
[TBL] [Abstract][Full Text] [Related]
32. Mitigation of sociocommunicational deficits of autism through oxytocin-induced recovery of medial prefrontal activity: a randomized trial.
Watanabe T; Abe O; Kuwabara H; Yahata N; Takano Y; Iwashiro N; Natsubori T; Aoki Y; Takao H; Kawakubo Y; Kamio Y; Kato N; Miyashita Y; Kasai K; Yamasue H
JAMA Psychiatry; 2014 Feb; 71(2):166-75. PubMed ID: 24352377
[TBL] [Abstract][Full Text] [Related]
33. Probiotic and Oxytocin Combination Therapy in Patients with Autism Spectrum Disorder: A Randomized, Double-Blinded, Placebo-Controlled Pilot Trial.
Kong XJ; Liu J; Liu K; Koh M; Sherman H; Liu S; Tian R; Sukijthamapan P; Wang J; Fong M; Xu L; Clairmont C; Jeong MS; Li A; Lopes M; Hagan V; Dutton T; Chan SP; Lee H; Kendall A; Kwong K; Song Y
Nutrients; 2021 May; 13(5):. PubMed ID: 34062986
[TBL] [Abstract][Full Text] [Related]
34. Oxytocin treatment attenuates amygdala activity in autism: a treatment-mechanism study with long-term follow-up.
Bernaerts S; Boets B; Steyaert J; Wenderoth N; Alaerts K
Transl Psychiatry; 2020 Nov; 10(1):383. PubMed ID: 33159033
[TBL] [Abstract][Full Text] [Related]
35. The Potential of Nasal Oxytocin Administration for Remediation of Autism Spectrum Disorders.
Okamoto Y; Ishitobi M; Wada Y; Kosaka H
CNS Neurol Disord Drug Targets; 2016; 15(5):564-77. PubMed ID: 27071789
[TBL] [Abstract][Full Text] [Related]
36. [Development of Novel Therapeutics for Core Symptoms of Autism Spectrum Disorder: An Integrative Approach of Clinical Trials, Neuroimaging, and Genomics].
Yamasue H
Brain Nerve; 2019 Sep; 71(9):971-980. PubMed ID: 31506399
[TBL] [Abstract][Full Text] [Related]
37. Cumulative Risk of the Oxytocin Receptor Gene Interacts with Prenatal Exposure to Oxytocin Receptor Antagonist to Predict Children's Social Communication Development.
Friedlander E; Yirmiya N; Laiba E; Harel-Gadassi A; Yaari M; Feldstein O; Mankuta D; Israel S
Autism Res; 2019 Jul; 12(7):1087-1100. PubMed ID: 31025834
[TBL] [Abstract][Full Text] [Related]
38. Oxytocin increases eye contact during a real-time, naturalistic social interaction in males with and without autism.
Auyeung B; Lombardo MV; Heinrichs M; Chakrabarti B; Sule A; Deakin JB; Bethlehem RA; Dickens L; Mooney N; Sipple JA; Thiemann P; Baron-Cohen S
Transl Psychiatry; 2015 Feb; 5(2):e507. PubMed ID: 25668435
[TBL] [Abstract][Full Text] [Related]
39. Intranasal oxytocin in the treatment of autism spectrum disorders: A multilevel meta-analysis.
Huang Y; Huang X; Ebstein RP; Yu R
Neurosci Biobehav Rev; 2021 Mar; 122():18-27. PubMed ID: 33400920
[TBL] [Abstract][Full Text] [Related]
40. Systematic review and meta-analysis of reported adverse events of long-term intranasal oxytocin treatment for autism spectrum disorder.
Cai Q; Feng L; Yap KZ
Psychiatry Clin Neurosci; 2018 Mar; 72(3):140-151. PubMed ID: 29232031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
